The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
British Journal of Cancer 116, 1402 (23 May 2017). doi:10.1038/bjc.2017.119
Authors: Rachna T Shroff, Mark Yarchoan, Ashley O'Connor, Denise Gallagher, Marianna L Zahurak, Gary Rosner, Chimela Ohaji, Susan Sartorius-Mergenthaler, Vivek Subbiah, Ralph Zinner & Nilofer S Azad
http://ift.tt/2oHPaix
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου